Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
United Therapeutics ( (UTHR) ) has issued an update.
On January 21, 2026, United Therapeutics’ board expanded its size to 13 members and appointed Kevin J. Tracey, M.D., a prominent researcher and biotech entrepreneur in inflammation and bioelectronic medicine, as a new director, granting him standard non-employee director equity awards and indemnification in line with existing company programs. On the same date, the board approved and put into effect an eleventh restatement of the company’s bylaws, introducing a cure process for certain shareholder director-nomination deficiencies, eliminating the board’s ability to require supermajority votes on routine matters, and lowering the shareholder voting threshold to amend the bylaws from 80% to a simple majority, changes that collectively enhance shareholder influence over governance and continue an active board-refreshment strategy.
The most recent analyst rating on (UTHR) stock is a Hold with a $546.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
The score is driven primarily by exceptionally strong financial performance (elite margins, large free cash flow, and a debt-free balance sheet). Earnings call commentary adds support via constructive long-term guidance and pipeline progress, while the technical picture is mixed with near-term softness versus the 20-day average. Valuation appears reasonable at a ~18.6 P/E, with no dividend data available to enhance the valuation component.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
United Therapeutics Corporation is a publicly traded biotechnology and pharmaceutical company that operates as a public benefit corporation, focusing on developing novel therapies for rare pulmonary diseases and advancing technologies to expand the availability of transplantable organs. The company positions itself as an unconventional, mission-driven innovator aiming to address unmet medical needs while delivering benefits to patients and other stakeholders.
Average Trading Volume: 472,648
Technical Sentiment Signal: Buy
Current Market Cap: $20.15B
See more insights into UTHR stock on TipRanks’ Stock Analysis page.